However, several studies associated the use of calcitonin with an increased risk of prostate cancer in men, prompting the removal of calcitonin from the list of approved therapies for osteoporosis by the European Medicine Agency (EMA) in 2012 [104]. This evidence concerns the gene CALCA and prostate carcinoma.